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Sensitization of human cancer cells to
gemcitabine by the Chk1 inhibitor MK-8776: cell
cycle perturbation and impact of administration
schedule in vitro and in vivo
Ryan Montano1,4, Ruth Thompson1,4, Injae Chung2, Huagang Hou3,4, Nadeem Khan3,4 and Alan Eastman1,4*
Abstract
Background: Chk1 inhibitors have emerged as promising anticancer therapeutic agents particularly when
combined with antimetabolites such as gemcitabine, cytarabine or hydroxyurea. Here, we address the importance
of appropriate drug scheduling when gemcitabine is combined with the Chk1 inhibitor MK-8776, and the
mechanisms involved in the schedule dependence.
Methods: Growth inhibition induced by gemcitabine plus MK-8776 was assessed across multiple cancer cell lines.
Experiments used clinically relevant “bolus” administration of both drugs rather than continuous drug exposures.
We assessed the effect of different treatment schedules on cell cycle perturbation and tumor cell growth in vitro
and in xenograft tumor models.
Results: MK-8776 induced an average 7-fold sensitization to gemcitabine in 16 cancer cell lines. The time of
MK-8776 administration significantly affected the response of tumor cells to gemcitabine. Although gemcitabine
induced rapid cell cycle arrest, the stalled replication forks were not initially dependent on Chk1 for stability. By
18 h, RAD51 was loaded onto DNA indicative of homologous recombination. Inhibition of Chk1 at 18 h rapidly
dissociated RAD51 leading to the collapse of replication forks and cell death. Addition of MK-8776 from 18–24 h
after a 6-h incubation with gemcitabine induced much greater sensitization than if the two drugs were incubated
concurrently for 6 h. The ability of this short incubation with MK-8776 to sensitize cells is critical because of the
short half-life of MK-8776 in patients’ plasma. Cell cycle perturbation was also assessed in human pancreas tumor
xenografts in mice. There was a dramatic accumulation of cells in S/G2 phase 18 h after gemcitabine administration,
but cells had started to recover by 42 h. Administration of MK-8776 18 h after gemcitabine caused significantly
delayed tumor growth compared to either drug alone, or when the two drugs were administered with only a
30 min interval.
Conclusions: There are two reasons why delayed addition of MK-8776 enhances sensitivity to gemcitabine: first,
there is an increased number of cells arrested in S phase; and second, the arrested cells have adequate time to
initiate recombination and thereby become Chk1 dependent. These results have important implications for the
design of clinical trials using this drug combination.
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Background
DNA damage activates cell cycle checkpoints that arrest
cell cycle progression and thereby provide time for
repair and recovery. This has led to the development
of checkpoint inhibitors as adjuvants to DNA damaging
agents with the anticipation that they will enhance
therapeutic activity. Chk1 is the primary checkpoint
protein against which many small molecule inhibitors
have been developed [1-3]. Chk1 is activated when the
kinases ATM and/or ATR detect double-strand breaks
or large single-strand regions of DNA, respectively.
Once activated, Chk1 phosphorylates and inactivates
CDC25 phosphatases that are required for CDK activa-
tion and cell cycle progression. Inhibition of Chk1 re-
sults in premature activation of CDC25 phosphatases
and CDK1/2, and progression through the cell cycle be-
fore adequate repair has occurred. Increased DNA dam-
age occurs as cells progress through S phase with a
damaged template, followed by lethal mitosis once they
have reached the G2 phase [4].
Antimetabolites such as gemcitabine and hydroxyurea
inhibit ribonucleotide reductase, thereby rapidly depleting
deoxyribonucleotide pools and stalling replication fork
progression. These agents do not directly induce DNA
breaks, and arrest occurs without the need for Chk1 acti-
vation. However, Chk1 stabilizes the stalled replication
forks and, when inhibited, the replication forks collapse
thus producing DNA double-strand breaks [5]. Hence,
there is a significant difference in the outcome of Chk1 in-
hibition depending on the type of DNA damage that oc-
curs; in the latter case, new lethal events occur where no
DNA damage existed previously. Consequently, we have
found that Chk1 inhibition can induce a far more dra-
matic sensitization to antimetabolites that induce this rep-
lication arrest compared to other DNA damaging agents
that activate Chk1 through the DNA damage-induced
checkpoint [6].
Gemcitabine is a deoxynucleoside analogue that is me-
tabolized to a deoxynucleotide triphosphate, a precursor
for incorporation into DNA, and to a deoxynucleotide
diphosphate that irreversibly inhibits ribonucleotide re-
ductase. As a consequence, low concentrations of gemci-
tabine rapidly deplete deoxyribonucleotide pools, inhibit
DNA synthesis and induce a long S phase arrest. Here
we focus on the combination of gemcitabine with the
Chk1 inhibitor MK-8776 [7]. We report the efficacy of
this combination in cell lines from many different can-
cers. We also report that the time of addition of MK-
8776 can significantly impact the response of tumor cells
to gemcitabine both in vitro and in xenograft tumor
models. The schedule dependence is critical because of
the relatively short half-life of MK-8776 in patients’
plasma [8]. These results have important implications
for the design of clinical trials of this combination.
Methods
Materials
Gemcitabine was obtained from Eli Lilly, Indianapolis, IN.
MK-8776 (previously known as SCH 900776) was pro-
vided by Merck, Kenilworth, NJ and dissolved in dimethyl-
sulfoxide [7]. The majority of cell lines are part of the
NCI60 panel and were obtained from the Develop-
mental Therapeutics Program, National Cancer Institute,
Bethesda and maintained in RPMI1640 medium plus
serum and antibiotics [9]. Other cell lines were obtained
from American Type Culture Collection (Manassas, VA).
All lines were used within three months of thawing from
frozen stocks. No further reconfirmation of their identity
was performed.
Cell analysis
Cell cycle analysis was performed by flow cytometry as de-
scribed previously [10]. For cell growth assays, cells were
seeded at low density (500–1000 cells) in 96-well plates
and then incubated with drugs for various schedules usu-
ally for 24 h (8 wells per concentration). Following treat-
ment, cells were washed and grown in fresh media for 6–7
days at 37°C. Prior to attaining confluence, cells were
washed, lysed, and stained with Hoechst 33258, as previ-
ously described [11]. Fluorescence was read on a micro-
plate spectrofluorometer (Spectramax M2). Results are
expressed as the concentration of drug that inhibited
growth by 50% (IC50).
Immunoblotting
Cells were harvested and analyzed as previously detailed
[12] with the following antibodies: phosphoserine-345-
Chk1, phosphoserine-296-Chk1, DNA-PK and γH2AX
(Cell Signaling); Chk1 (Santa Cruz Biotechnology);
phospho-2056-DNA-PK (Abcam); and actin (Sigma).
Immunofluorescence
Cells were cultured on glass coverslips, incubated with
gemcitabine and/or MK-8776, and fixed with 3% para-
formaldehyde (20 min at room temperature). The cells
were then washed 4 × 15 min in PBS-T (PBS containing
0.15% BSA and 0.1% Triton-X-100). Slides were then
incubated with 200 ng/ml anti-Rad51 (Santa-Cruz) over-
night, washed in PBS-T and incubated with Alexa-555
conjugated goat anti-rabbit IgG (Invitrogen) at 1:1000
dilution for 1 h. DAPI (1 μg/mL) was added to the final
wash and the coverslips were mounted using Prolong
Gold Antifade (Invitrogen). Confocal images were ac-
quired using a Zeiss LSM 510 microscope.
Analysis of tumor xenografts
All animal procedures were performed in strict accordance
with the NIH Guide for the Care and Use of Laboratory
Animals and approved by the Institutional Animal Care
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and Use Committee at Dartmouth. To generate tumor xe-
nografts, 2 × 106 AsPC-1 or MiaPaCa-2 pancreas cancer
cells were injected into the flanks of athymic nu/nu mice.
Drug treatments began after the tumors had reached
100 mm3. Gemcitabine was administered at 150 mg/kg i.p.
in phosphate buffered saline while MK-8776 was adminis-
tered at 50 mg/kg i.p. in (2-hydroxypropyl) β-cyclodextrin,
45% w/v solution in water (Sigma). These doses were se-
lected based on a prior publication with these agents [7].
The schedules of administration varied with experiment
and are described in the results. Tumors were measured
with calipers in two dimensions and volume calculated
based on the equation volume = π/6 × length × width2.
The comparisons between groups at each time point were
made using a student’s t test for unpaired samples. The
tests were two-sided and a change with a p-value <0.05
was considered statistically significant.
Some tumors were harvested, fixed in formalin, and serial
sections were stained with anti-Ki67 (Vector Laboratories)
and anti-geminin (Santa-Cruz) in the Research Pathology
Shared Resource. For each tumor, at least 2 fields from
each of 2 sections were photographed, each field represent-
ing about 1000 cells; 2–4 individual tumors were scored at
each time point. The number of cells positive for geminin
was expressed as a percentage of those positive for Ki67.
Results
Impact of MK-8776 on gemcitabine-induced cytotoxicity
We previously analyzed MDA-MB-231 and MCF10A
cell lines for sensitivity to gemcitabine alone or when
combined with MK-8776 [6]. This analysis has now been
expanded to a large panel of cell lines (Table 1). In this
assay, cells were incubated with drugs for 24 h, and cell
growth was then assessed after an additional 6–7 days.
The results are expressed as the IC50 for gemcitabine
alone or when incubated with low (200 nmol/L) or high
(2 μmol/L) MK-8776; these concentrations were selected
based on our prior experience showing differential sen-
sitivity of cell lines to this drug [6]. The cells exhibit a
wide range of sensitivity to gemcitabine alone (3 – 83
nmol/L), but concurrent incubation with 2 μmol/L MK-
8776 resulted in an IC50 of <6.5 nmol/L for all the cell
lines. This reflected a 4–66 fold (median 7) sensitization
to gemcitabine. We previously noted that some cell lines
are particularly sensitive to MK-8776 alone; these in-
cluded U2OS, A498 and TK10 [6]. Our expanded screen
has now identified AsPC-1 as sensitive to MK-8776 (IC50
0.5 μmol/L following a 24 h incubation and assayed after 7
days). Most of the other cell lines tolerated 10 μmol/L
MK-8776 for 24 h. For the sensitive cell lines, it was not
possible to determine an IC50 for gemcitabine in combin-
ation with 2 μmol/L MK-8776. However in these cell lines
sensitization was still observed when combined with 200
nmol/L MK-8776. TK10 cells are an exception in this
regard as they are very sensitive to gemcitabine alone so
were not sensitized further.
Cell cycle perturbation induced by gemcitabine and
MK-8776
We next determined whether the concentration of gemci-
tabine that inhibited growth correlated with S phase arrest
(Figure 1A). The breast tumor cell line MDA-MB-231 was
incubated with gemcitabine for 24 h and the extent of cell
cycle perturbation was assessed over the following 48 h.
Cells incubated with 3–6 nmol/L gemcitabine accumulated
in mid to early S phase by 24 h and appeared to recover
completely within 24 h of drug removal. Cells incubated
with 12 nmol/L gemcitabine arrested early in S phase at
24 h, progressed further into S phase 24 h after drug
removal, and had almost completely recovered by 48 h.
This pattern can be compared to the IC50 of 18 nmol/L in
this cell line (Table 1). In contrast, cells incubated with
50 nmol/L gemcitabine showed very little recovery, and a
sub-G1 population began to appear 48 h after release.
We performed parallel experiments to assess cell cycle
perturbation when gemcitabine was combined with MK-
8776 (Figure 1A). When cells were co-incubated with
this combination for 24 h, there was little difference in
the cell cycle distribution compared to treatment with
gemcitabine alone except at the lowest concentration
(1.5 nmol/L) at which there was a further increase in S
phase cells. These cell cycle perturbations are important
as they relate to the mechanism of action of gemcita-
bine. Gemcitabine both inhibits ribonucleotide reductase
and is incorporated into DNA to cause strand termin-
ation. In the face of DNA damage, Chk1 inhibition nor-
mally abrogates S phase arrest and drives cells into G2
as we previously observed with the topoisomerase I in-
hibitor SN38 [13]. However, inhibition of Chk1 did not
abrogate S phase arrest induced by gemcitabine. This is
explained by the inhibition of ribonucleotide reductase;
as there are no deoxyribonucleotides that can be incor-
porated into DNA, inhibition of Chk1 can not force cells
to progress through S phase. This suggests that the ma-
jority of the effect of gemcitabine in these experiments is
due to inhibition of ribonucleotide reductase.
The most notable impact of MK-8776 occurs following
removal of the drugs. After an additional 48 h, there is very
little recovery except at the lowest concentration of gemci-
tabine. The partial recovery at 3 nmol/L gemcitabine is
consistent with the IC50 for gemcitabine when combined
with 2 μmol/L MK-8776 (Table 1). Hence, this enhanced
cytotoxicity occurs at concentrations of gemcitabine that
transiently perturb the cell cycle and is therefore consistent
with disruption of replication fork progression as discussed
further below. At higher concentrations of gemcitabine,
there is only slight movement of the cells in S phase and
an increasing proportion of cells appear with sub-G1 DNA
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content. These results are consistent with the cytotoxicity
data showing the marked sensitization that occurs when
MK-8776 is added to gemcitabine.
Activation of the DNA damage response by gemcitabine
and MK-8776
To further investigate the S phase arrest and whether it is
caused primarily by inhibition of ribonucleotide reductase
or by direct DNA damage, we asked whether these concen-
trations of gemcitabine activated Chk1. After a 24 h incu-
bation of MDA-MB-231 cells with 50 nmol/L gemcitabine,
there was marked phosphorylation of Chk1 at both ser345
and ser296 which suggests the presence of DNA dam-
age, probably single-stranded regions in DNA as there
was negligible phosphorylation either H2AX or DNA-
protein kinase which should appear if there are DNA
double-strand breaks (DSB) (Figure 2A). In contrast, no
detectable phosphorylation of Chk1 was observed below
12 nmol/L suggesting little direct DNA damage occurs
despite the fact that the cells arrest in early S phase at
these concentrations.
Incubation of cells with MK-8776 alone for 24 h induced
low level phosphorylation of ser345-Chk1. We have previ-
ously reported that this phosphorylation occurs prior to
Table 1 Sensitivity of cell lines to gemcitabine alone or in combination with MK-8776
A. Gemcitabine and MK-8776 0–24 h
Cell line IC50 (nmol/L)
Gem alone Gem+ 200 nmol/L MK-8776 Gem+ 2 μmol/L MK-8776
U251 36.6 ± 8.8 15 ± 5.5 (2.4) 6.5 ± 1.5 (5.6)
HCT115 25 ± 5 13.8 ± 1.3 (1.8) 5.1 ± 1.1 (4.9)
SW620 83.3 ± 16 30 ± 0 (2.8) 4.8 ± 0.9 (17.4)
IGROV-1 25 ± 5 5.2 ± 1.1 (4.8) 3.5 ±1.5 (7.1)
HCT116 13.8 ± 1.3 5.5 ± 0.5 (2.5) 3.3 ± 0.3 (4.2)
MCF10A 13 ± 6.1 5.2 ± 2.4 (2.5) 2.8 ± 1.1 (4.6)
MiaPaCa-2 26.5 ± 4.3 4.2 ± 0.8 (6.3) 2.2 ± 1.2 (12.0)
MDA-MB-231 18.5 ± 7.1 4.4 ± 0.81 (4.2) 1.5 ± 0.44 (12.3)
HCC2998 15 ± 5 3.8 ± 1.3 (3.9) 1.5 ± 0.4 (10.0)
U87 7.5 ± 1.3 2.7 ± 0.4 (2.8) 1.5 ± 0.3 (5.0)
MDA-MB-435 8.6 ± 3.2 1.5 ± 1.5 (5.7) 0.4 ± 0 (21.5)
SNB19 10 ± 3.5 1.3 ± 0.08 (7.7) 0.15 ± 0.03 (66.7)
U20S 32.5 ± 2.5 10.5 ± 4.5 (3.1) DEAD
A498 22.5 ± 2.5 3.5 ± 1.5 (6.4) DEAD
TK10 3.4 ± 1.6 2.8 ± 1.3 (1.2) DEAD
AsPC-1 14 ± 1 3.3 ± 0.2 (4.2) DEAD
B. Gemcitabine 0–24 h; MK-8776 18–24 h
U251 36.6 ± 8.8 32.5 ± 2.5 (1.1) 12.5 ± 2.5 (2.9)
MDA-MB-231 18.5 ± 7.1 12.5 ± 5.5 (1.5) 4.6 ± 0.8 (4.0)
U87 7.5 ± 1.3 5 ± 0.6 (1.5) 2.8 ± 0.16 (2.7)
MDA-MB-435 8.6 ± 3.2 8 ± 2 (1.1) 0.77 ± .73 (11.2)
AsPC-1 14 ± 1 7.8 ± 2.2 (1.8) 1.7 ± 0.23 (8.2)
C. Gemcitabine 0–6 h; MK8776 18–24 h
U251 250 ± 51 187 ± 38 (1.3) 113 ± 18.5 (2.2)
MiaPaCa-2 175 ± 25 90 ± 35 (1.9) 39 ± 1 (4.5)
MDA-MB-231 60.5 ± 10.3 35 ± 9.6 (1.7) 19.2 ± 2.3 (3.2)
U87 12.6 ± 3.9 9 ± 2.1 (1.4) 5.3 ± 0.9 (2.4)
MDA-MB-435 41.6 ± 19.7 22.5 ± 7.5 (1.8) 5.5 ± 2.5 (7.6)
SNB19 75 ± 0 35 ± 5 (2.1) 16.5 ± 1.5 (4.5)
AsPC-1 115 ± 11.9 53.3 ± 6.7 (2.2) 12 ± 1.7 (9.6)
Following treatment as indicated, drugs were removed and cells were incubated for an additional 5–7 days and the IC50 for gemcitabine determined.
Values reflect mean +/− SEM with n = 2–5; parenthesis = fold sensitization.
“DEAD” =MK-8776 alone markedly suppressed growth so no cumulative cytotoxicity calculable.
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Figure 1 (See legend on next page.)
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the detection of DNA damage as assessed by γH2AX [14],
hence this is likely attributable to the inhibition of Chk1
preventing the normal feedback dephosphorylation by
protein phosphatase 2A such that ongoing phosphoryl-
ation by ATR enhances phosphorylation of Chk1 [15].
When 1 μmol/L MK-8776 was combined with gemcita-
bine, even at the lowest concentrations tested, there was
an increased phosphorylation of ser345-Chk1 but no
phosphorylation of ser296-Chk1, an autophosphorylation
site, consistent with inhibition of Chk1. There was also a
dramatic increase in γH2AX and phospho-DNA-PK con-
sistent with the collapse of replication forks. Contrary to a
prior report [16], we did not see degradation of Chk1 by
this combination, except marginally at the highest concen-
tration, perhaps due to the much lower concentrations of
gemcitabine used in the current study.
We next investigated the kinetics of phosphorylation
of Chk1 and H2AX during incubation with 1–10 nmol/L
gemcitabine, the concentrations around the IC50 con-
centrations of gemcitabine in combination with MK-
8776 (Table 1). As anticipated from Figure 2A, there was
negligible phosphorylation of Chk1 and H2AX in cells
incubated with gemcitabine alone (Figure 2B). However,
when the drugs were combined, high phosphorylation
levels were observed, but this did not occur until 16 h.
One possibility for this delay in the appearance of
phospho-Chk1 and γH2AX is that the forks do not ar-
rest rapidly. However, incubation of cells with 10 nmol/L
gemcitabine caused complete suppression of DNA syn-
thesis within 3 h (data not shown; but is also evident
from the decrease in G2/M population after a 6-h incu-
bation in Figure 1B).
Impact of delaying addition of MK-8776 to
gemcitabine-arrested cells
The above results suggest that, for the first 16 h of ar-
rest, the replication forks do not depend on Chk1 for
stability, but the stalled forks evolve with time to be-
come more Chk1 dependent. To further test the time
frame of Chk1 dependence, we added MK-8776 at differ-
ent times after gemcitabine (Figure 2C). When added
after 16 h, marked phosphorylation of Chk1 and H2AX
occurred within 2 h consistent with the hypothesis that
replication forks become more Chk1 dependent over
time. To more directly compare the extent of DNA
damage induced by these different schedules, we incu-
bated cells with gemcitabine for 24 h, and added MK-
8776 for the final 2, 4, 6 or 24 h (i.e., the latter being
concurrent incubation). Incubation for just the final 4 h
induced as much γH2AX as the concurrent incubation
(Figure 2D). Hence, it is only necessary to add MK-8776
for a brief period once the replication forks have evolved
to be Chk1 dependent.
Considering that the delayed addition of MK-8776 was
as effective at inducing γH2AX, we assessed the impact
of this schedule on cytotoxicity. In these experiments,
gemcitabine was added for 24 h while MK-8776 was
added for only the final 6 h (Table 1B). Marked sen-
sitization was again observed, with only a slight decrease
in extent of sensitization (~2 fold) compared to a 24 h
concurrent treatment.
Impact of MK-8776 on gemcitabine-induced homologous
recombination
Stalled replication forks provide a substrate for homolo-
gous recombination that can be visualized as the accumu-
lation of nuclear RAD51 foci, and this step is dependent
on Chk1 [16,17]. Gemcitabine has been shown to induce
RAD51 foci after 24 h although the time of onset was
not previously investigated [16]. To assess the kinetics of
recombination following addition of gemcitabine, MDA-
MB-231 cells were incubated with 10 nmol/L gemcitabine
for 0–24 h, then fixed and stained for RAD51 foci. The
number of cells with RAD51 foci began to increase at 8 h,
but increased to about 35% of the cells by 16 and 24 h
consistent with the percent of cells in S phase at the time
of addition of gemcitabine (Figure 3A). It is worth noting
that the cells still lack deoxyribonucleotides so the appear-
ance of RAD51 foci does not reflect functional recom-
bination but rather stalled recombination. This stalled
recombination is eventually reversible once gemcitabine is
removed as the cells were able to recover from this con-
centration of drug (Figure 1A).
When MK-8776 was added to gemcitabine-treated
cells (i.e., at 18 h), RAD51 foci disappeared (Figure 3B).
Hence, it appears that RAD51 protects the DNA from
further damage, even though recombination has stalled,
but when Chk1 is inhibited, Rad51 foci dissociate and
replication forks collapse.
Cell cycle perturbation and cytotoxicity induced by brief
incubation with gemcitabine
The 6 h pulse of MK-8776 was selected above as it is
consistent with the short half-life in patient plasma
whereby concentrations above 1 μmol/L are only main-
tained for 6 h [8]. In a similar manner, gemcitabine is
(See figure on previous page.)
Figure 1 Impact of gemcitabine and MK-8776 on cell cycle perturbation of MDA-MB-231 cells. A. Cells were incubated with 0 – 50 nmol/L
gemcitabine for 24 h without (left) or with (right) 1 μmol/L MK-8776. The drugs were then removed and cells incubated for an additional 24 or 48 h.
Cells were then analyzed for DNA content by flow cytometry. B. Similar to A except cells were incubated with gemcitabine for only the first 6 h, while
MK-8776 was added only from 18–24 h.
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administered to patients as a bolus rather than a 24 h
continuous incubation. While the parent drug has a
short half-life in plasma, the activated nucleotides have
a long intracellular half-life and consequently inhibit
ribonucleotide reductase for a long period of time [18].
In addition, the inhibition of ribonucleotide reductase
is irreversible further preventing recovery of the cells.
However, the kinetics of cell cycle arrest following a
bolus treatment have not been studied previously either
in vitro or in vivo. This led us to investigate the conse-
quences of a brief incubation with gemcitabine (nomin-
ally 6 h in these experiments). MDA-MB-231 cells were
incubated with gemcitabine for 6 h, then the drug was
removed and cell cycle perturbation assessed over the
following 66 h (Figure 1B). In general, the results are
similar to those observed following a 24 h continuous
incubation with gemcitabine although about 4-fold
higher drug concentration was required to induce arrest
at mid or early S phase. The cells also recovered even at
the highest concentration tested which was approxi-
mately the IC50 for a 6-h incubation with gemcitabine
alone (Table 1C). However, when MK-8776 was added
from 18–24 h, recovery was markedly reduced with cells
remaining in S phase at the higher concentrations and
an increase in sub-G1 population was apparent.
To further investigate the optimal time of addition of
MK-8776, we incubated cells with gemcitabine for 6 h,
then added MK-8776 either concurrently or for 6-h
periods at various times after removal of gemcitabine
(Figure 4). While concurrent incubation decreased the
IC50 for gemcitabine by almost 50%, the greatest sensi-
tization was observed when MK-8776 was administered
from 18–24 h (i.e., 12–18 h after removal of gemcita-
bine). This experiment was extended to three other cell
lines, and all showed the same result whereby addition
of MK-8776 from 18–24 h had the greatest impact on
the IC50 for gemcitabine.
The impact of this schedule (gemcitabine 0–6 h and
MK-8776 18–24 h) was assessed in additional cell lines
Figure 2 Concentration and schedule dependence for the
induction of DNA damage by gemcitabine plus MK-8776 in
MDA-MB-231 cells. A. Cells were incubated with the indicated
concentration of gemcitabine for 24 h without, or concurrently with
1 μmol/L MK-8776. Cell lysates were analyzed by western blotting.
B. Cells were incubated with 1–10 nmol/L gemcitabine for 0 – 24 h,
without or with 1 μmol/L MK-8776. The 24-h sample incubated with
1 nmol/L gemcitabine was run on the other western blots to
compare band intensities. C. Cells were incubated with or without
gemcitabine for 0–24 h, and MK-8776 was added for the last 2 h.
D. Cells were incubated with or without gemcitabine for 24 h, and
MK-8776 was added concurrently or for the final 6, 4 or 2 h. Parallel
cultures were incubated with MK-8776 alone. Cell lysates were
analyzed by western blotting.
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(Table 1C). The brief incubation with gemcitabine was
generally 2–8 fold less cytotoxic than the 24 h continuous
incubation. However, the addition of 2 μmol/L MK-8776
still induced 2–10 fold sensitization to gemcitabine.
Cell cycle perturbation induced by gemcitabine in vivo
These experiments were extended to xenograft models
to determine the extent of cell cycle arrest following
administration of gemcitabine. Ki67 is often used as a
marker of proliferation but cells at any phase of the cell
cycle, except Go, are positive for this antigen. In contrast,
only cells in S and G2 express geminin [19]. Accordingly,
the ratio of geminin/Ki67 reflects the proportion of cells
in the cell cycle (Ki67 positive) that are in S or G2 (gemi-
nin positive) at the time of harvest. This ratio (expressed
here as a percentage) corrects for large differences in
Ki67-positive cells throughout a tumor which can result
from hypoxia or limited nutrient supply.
In preliminary studies, we found that some tumor models
were not very amenable to this analysis. For example, the
MDA-MB-231 cells exhibited a very narrow rim of prolifer-
ating cells surrounding a large Ki67-negative center. Several
other tumors including U87 glioma expressed very low
levels of geminin. However, AsPC-1 and MiaPaCa-2 pan-
creas xenografts showed good distribution of both antigens
throughout the tumor and were therefore used in these
studies. These cells were first analyzed in vitro to confirm
their cell cycle perturbation following gemcitabine. Both
cell lines showed S phase arrest and recovery following a 6-
h incubation with gemcitabine that was comparable to that
seen in MDA-MB-231 cells but at 4–8 fold higher con-
centration (Additional file 1: Figure S1 and Figure S2).
Addition of MK-8776 from 18 – 24 h (12 h after removal
of gemcitabine) caused sustained arrest of the cells that
did not resolve by 72 h (similar to MDA-MB-231 cells).
Mice bearing these pancreas xenografts were adminis-
tered 150 mg/kg gemcitabine and tumors harvested after
either 18 or 42 h. The tumors were then stained for Ki67
and geminin. In untreated tumors, Ki67-positive cells were
distributed through much of the tumor, but in those areas
where it was most abundant, it still only represented about
half of the cells (Additional file 1: Figure S3). Serial sec-
tions of the slides showed geminin had a similar distribu-
tion, but with a lower frequency (40-50% of Ki67-positive
cells; Figure 5A). Treatment with gemcitabine increased
the frequency of geminin-positive cells to 83% at 18 h in
AsPC-1 xenografts and 95% in MiaPaCa2, but the cells
began to recover by 42 h. These results show that gemci-
tabine induces a large but transient arrest of the cells in
S phase at 18 h.
Figure 3 Confocal imaging of RAD51 foci. A. MDA-MB-231 cells were cultured on coverslips with 10 nmol/L gemcitabine for 0 – 24 h then
stained for RAD51 foci. 100 cells were scored for each condition. Values reflect the mean and range of 2 independent experiments. B. Cells were
untreated or incubated with either 1 μmol/L MK-8776 for 6 h, 10 nmol/L gemcitabine for 24 h, or 10 nmol/L gemcitabine 0–24 h with 1 μmol/L
MK-8776 added for the last 6 h. Cells were scored as in A. Significance was calculated using an unpaired t-test.
Montano et al. BMC Cancer 2013, 13:604 Page 8 of 14
http://www.biomedcentral.com/1471-2407/13/604
Impact of gemcitabine plus MK-8776 on tumor growth
delay
The two pancreas xenografts were also used to assess the
response to gemcitabine plus MK-8776. Tumor-bearing
mice were administered gemcitabine alone, MK-8776 alone
or in combination using two different schedules: MK-8776
was administered either 30 min or 18 h after gemcitabine.
Mice were treated each week for three weeks (days 1, 8
and 15) and tumor volume and mouse weight recorded.
Untreated AsPC-1 tumors doubled in volume over ap-
proximately 22 days whereas MiaPaCa-2 doubled in ap-
proximately 10 days (Figure 5B and C). Administration of
MK-8776 alone was not significantly different than control
in either model. Gemcitabine treatment caused a signifi-
cant decrease in growth rate, but did not cause any tumor
regression. MK-8776 administered 30 min after gem-
citabine was not significantly different than gemcitabine
alone. In contrast, when MK-8776 was administered 18 h
after gemcitabine, the tumor growth rate was significantly
slower than all other groups, and in AsPC-1, partial tumor
regression was observed (about 25% by day 10); partial re-
covery occurred after the third treatment, although the
tumor size remained significantly less than all other treat-
ment groups throughout the experiments. No obvious tox-
icity to the mice was observed and there was no significant
difference in weight between any of the groups, albeit a
slight (5%) loss of weight appeared to occur transiently
following administration of MK-8776 on all schedules
(data not shown). This experiment confirms that delaying
administration of MK-8776 for 18 h after gemcitabine is
well tolerated and has the greater therapeutic potential.
Discussion
Chk1 participates in multiple functions in a cell [3]. It was
originally recognized as a mediator of the DNA damage
response, preventing cell cycle progression so that cells
could repair DNA damage. The underlying mechanism
involves Chk1-mediated inhibition of CDC25, thereby
preventing activation of CDK1 and 2. Inhibition of Chk1
leads to activation of CDK1/2, cell cycle progression and
Figure 4 Identification of the optimum schedule for combining gemcitabine and MK-8776. The four indicated cell lines were incubated
with gemcitabine for 6 h, and 2 μmol/L MK-8776 was added concurrently (column 2) or for a 6-h period at various times after removal of
gemcitabine. After removal of drugs, cells were incubated for an additional 6–7 days and cell growth assayed based on DNA content. Experiments
were performed in a 96 well format and results are expressed as 50% inhibition of growth of the culture. The values represent the mean and
range for duplicate experiments. In addition, the mean and SEM of the values for additional experiments at 0 and 18–24 are presented in
Table 1C.
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Figure 5 (See legend on next page.)
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aberrant mitosis. Recently, it has been recognized that
some cell lines are hypersensitive to brief inhibition of
Chk1 alone, with γH2AX foci and/or DNA double-strand
breaks appearing within 6 h [6,14,20]. This damage occurs
only in S phase cells and is also mediated by activation of
CDK2. In addition, Chk1 is now recognized as having
additional roles in replication fork stability, replication
origin firing and homologous recombination, and it is the
latter of these roles that appears important for the efficacy
of the combination of gemcitabine with MK-8776. Mech-
anistically, homologous recombination results when Chk1
phosphorylates the C-terminal domain of BRCA2 which
then interacts with and recruits RAD51 to single-stranded
DNA. In addition Chk1 can directly phosphorylate RAD51
and this is also required for recruitment of RAD51 to
single-stranded DNA [17,21]. Our results demonstrate
that inhibition of Chk1 can also result in dissociation of
RAD51 from DNA which we suggest is due to the dy-
namic status of regressed replication forks which likely
shorten or grow in length continuously and thereby dis-
place RAD51.
These different functions of Chk1 can explain why
Chk1 inhibitors exhibit variable efficacy in sensitizing
cells to DNA damaging agents. Our previous experi-
ments involved incubation of cells with the topoiso-
merase I inhibitor SN38 [4,6]. Replication forks collide
with the inhibited topoisomerase complex creating DNA
breaks that rapidly activate Chk1 and prevent cell cycle
progression. Yet while inhibition of Chk1 induced cell
cycle progression, it had little impact on overall cytotox-
icity because lethal breaks were already induced by
SN38 alone. In contrast, when gemcitabine or hydroxy-
urea inhibit ribonucleotide reductase, replication stalls
rapidly and independently of Chk1. Indeed, we previ-
ously demonstrated that hydroxyurea can arrest DNA
replication without activating Chk1, and this observation
is reiterated here at low concentrations of gemcitabine
[6]. Upon removal of gemcitabine, these arrested cells
are able to recover. However, inhibition of Chk1 rapidly
induces collapse of replication forks, and this is new DNA
damage that dramatically enhances cell killing. Other in-
vestigators have observed activation of Chk1 upon incu-
bation with either hydroxyurea or gemcitabine, but in
general those experiments involved higher concentrations
of each drug that exceed those needed to arrest the cells
[22-24]. We have observed slight activation of Chk1 when
western blots are over-exposed, but this level of phosphor-
ylation is far lower than observed after replication forks
have collapsed as a consequence of Chk1 inhibition. Simi-
lar observations were made in a study of gemcitabine
alone which showed phosphorylation of Chk1, but a sub-
sequent paper also showed this to be negligible compared
to that induced by concurrent inhibition of Chk1 [25,26].
In the case of cells incubated with gemcitabine alone, we
question whether the low level activation of Chk1 is due
to incorporation of gemcitabine into DNA and the chain
termination that then occurs rather than to the inhibition
of ribonucleotide reductase.
Here, we show that MK-8776 markedly sensitizes mul-
tiple cell lines to gemcitabine. In further dissecting the
mechanism, we noted that γH2AX did not appear until
about 16 h of co-treatment. We therefore delayed the
addition of MK-8776 and demonstrated that, when added
for the final 4 h of a 24-h incubation of gemcitabine, it in-
duced as much γH2AX signal as it did when incubated
concurrently with gemcitabine for the entire 24 h. Our re-
sults demonstrate that stalled replication forks evolve with
time to become more Chk1 dependent, and this correlates
with a delay in loading of Rad51 onto DNA. When Chk1
was inhibited, these Rad51 foci disappeared and very
strong γH2AX signal was observed. Evolution of stalled
replication forks and delayed appearance of RAD51 foci
have previously been observed during incubation with hy-
droxyurea, but it was concluded that RAD51-dependent
recombination occurred in response to collapsed repli-
cation forks [27]. Here we observed very few γH2AX-
positive foci prior to recombination, but a dramatic in-
crease once RAD51 loading was prevented by inhibiting
Chk1. This implies that the appearance of γH2AX is a
consequence of inhibiting recombination and not the
stimulus for recombination. That inhibition of recombin-
ation is important for the observed sensitization is also
suggested by the TK10 cells which were sensitive to gem-
citabine alone, and were not further sensitized by MK-
8776. This cell line has been reported to have a defect in
recombination which would explain this observation [28].
(See figure on previous page.)
Figure 5 Impact of gemcitabine and MK-8776 on two pancreas tumor xenografts. A. Mice were administered 150 mg/kg gemcitabine and
tumors harvested at 18 h and 42 h. Serial sections from the tumors were stained for Ki67 and geminin and the ratio of geminin/Ki67 expressed as
a percentage. Results represent the mean and SEM for at least 2 sections from 2–4 mice. B. Mice bearing AsPC-1 tumors were administered 150
mg/kg gemcitabine on days 1, 8, 15 (arrows); or 50 mg/kg MK-8776; or the combination of these two drugs with MK-8776 given either 30 min or
18 h after gemcitabine. Data are expressed as mean and SEM for each time point. “n” represents the number of mice in each group. After day 5,
all gemcitabine-treated groups were significantly different from untreated mice (p < 0.05). Treatment with gemcitabine followed by MK-8776 after
30 min was not significantly different than gemcitabine alone. Treatment with gemcitabine followed by MK-8776 after 18 hours was significantly
different from gemcitabine alone or when combined with MK-8776 after 30 minutes (p < 0.05). C. Mice bearing MiaPaCa-2 tumors were treated
as in B. After 12 days, treatment with gemcitabine followed by MK-8776 after 18 hours was significantly different from either gemcitabine alone
or when combined with MK-8776 after 30 minutes (p < 0.05).
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The requirement for only a brief incubation with MK-
8776 to enhance cytotoxicity is an important observation
given that, in clinical trials, the plasma concentration of
MK-8776 was shown to exceed 1 μmol/L for only about
6 h [8]. MK-8776 dissociates rapidly from Chk1 when
the drug is removed (data not shown), so it is unlikely
that Chk1 will remain inhibited significantly beyond 6 h.
We extended these experiments to more closely reflect
the clinical situation by incubating cells briefly with
gemcitabine, and then permitting the cells to recover.
Because ribonucleotide reductase remains inhibited for a
long time, it took several days for the cells to recover;
the rate of recovery depended on the concentration of
gemcitabine. Cells in G1 also progressed into S phase
during this time, so the number of cells potentially sus-
ceptible to Chk1 inhibition continued to increase. Hence
there are two reasons why delayed addition of MK-8776
can enhance sensitivity to gemcitabine: first, there is an
increased number of cells arrested in S phase, and sec-
ond, the arrested cells have been given adequate time to
become Chk1 dependent (i.e., to initiate recombination).
The current experiments indicated that addition of MK-
8776 at 18 h provided the greatest decrease in IC50 for
gemcitabine in four cell lines (Figure 4). However, these
experiments only reflect growth inhibition, and the S
phase arrest at these low concentrations was very tran-
sient. Higher concentrations of gemcitabine induce a
longer arrest with more cells accumulating in S phase.
Consequently, it is possible that later addition of MK-
8776 may have improved cell killing as the cells newly
arrested in S phase at 18 h may not yet have become
Chk1 dependent.
To more directly assess the relevance of these in vitro
observations, we assessed the S/G2 phase arrest that oc-
curred in two different tumor models in vivo. This was
quantified as the ratio of geminin-positive to Ki67-
positive cells. Eighteen hours after administration of 150
mg/kg gemcitabine, there was a marked increase in
geminin-positive cells suggesting that up to 83-95% of
the Ki67-positive cells were in S or G2 phase. By 42 h,
this percentage had partially reverted to the starting
value reflecting recovery of the cells. This dose of gemci-
tabine is considered equivalent to a dose of 450 mg/m2
in patients, which is about half the standard dose admin-
istered (1000 mg/m2). We are currently performing a
clinical trial to assess the S/G2 phase arrest that occurs
in patients receiving gemcitabine as a guide for subse-
quent administration of a Chk1 inhibitor.
Finally, we assessed the impact of schedule on the re-
sponse of human tumor xenografts to the combination
of gemcitabine and MK-8776. The results clearly dem-
onstrated that administration of MK-8776 18 h after
gemcitabine, but not 30 min after, caused significant de-
crease in tumor growth compared to gemcitabine alone,
consistent with the observations made in vitro. This
conclusion held in two different tumor models. The
pharmacokinetics of MK-8776 in mice is currently being
assessed, and we believe it may be possible to increase
the length of exposure of tumors to drug and thereby
further enhance the therapeutic response.
The clinical development of Chk1 inhibitors has taken
many years. The first candidate, UCN-01, was a broad kin-
ase inhibitor but had unfavorable pharmacokinetic proper-
ties [29,30]. Three subsequent Chk1 inhibitors that entered
clinical trial, AZD7762, XL9844 and PF-00477736, have
been discontinued; whether this is due to mechanism-
based toxicity or off-target effects remains to be deter-
mined (the latter drug was reportedly terminated for busi-
ness reasons rather than concerns for safety or efficacy;
www.clinicaltrials.gov). Clinical trials are currently ongoing
with LY2606318, LY2606368 and GDC-0425. In most
cases, these inhibitors are being studied in combination
with gemcitabine or, in one case, pemetrexed [31]. One
issue with all these drugs is that they inhibit several other
targets, and in most cases this includes Chk2, although the
published information is limited. Indeed, there are cur-
rently no publications reflecting the preclinical develop-
ment of these other agents with which we can compare
our current results.
MK-8776 may have an advantage over other Chk1 in-
hibitors in being much more selective for Chk1 and add-
itionally, it does not inhibit Chk2 [7]. MK-8776 has
completed Phase I clinical trials in combination with gem-
citabine although the schedule was based on a 30 min
interval between the two drugs. The results of a second
Phase I clinical trial in combination with cytarabine has
just been reported [8]. In this case a different schedule was
used: cytarabine was administered as a 72 h infusion with
MK-8776 given on day 2 and 3 [8]. The schedule with
other Chk1 inhibitors could vary depending upon the time
frame over which it can inhibit Chk1, and the DNA dam-
aging agent with which it is combined. For example,
LY2603618 has recently been shown to have a plasma
half-life of 5 – 25 h, though whether this drug remains
bioavailable throughout this time frame is unknown [31].
Our results provide justification for a schedule of adminis-
tration whereby gemcitabine is administered 18 h prior to
MK-8776, and this justification should apply to clinical
trials of gemcitabine with any other Chk1 inhibitor.
Conclusions
Chk1 inhibitors have shown great promise in preclinical
experiments, particularly when used to sensitize tumors
to antimetabolites such as gemcitabine. However, prior
experiments have not defined the best schedule for ad-
ministration of these two drugs. We have identified two
reasons that justify delaying administration of MK-8776
until 18 h after gemcitabine: first, there is an increased
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number of cells arrested in S phase; and second, the
arrested cells become increasingly dependent on Chk1
over time due to their reliance on homologous recom-
bination. Consequently, the delayed administration of
MK-8776 provides greater tumor growth delay in xeno-
graft models. These results have important implications
for the design of clinical trials of this drug combination.
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Additional file 1: Montano et al. Sensitization of human cancer cells
to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation
and impact of administration schedule in vitro and in Vivo. Figure S1.
Impact of gemcitabine and MK-8776 on cell cycle perturbation of
AsPC-1 cells. Cells were incubated with 0 – 200 nM gemcitabine for 6 h,
then the drug was removed and cells incubated for up to 72 h (left).
One set of cells (right) were also incubated with 1 μM MK-8776 from
18-24 h. Figure S2. Impact of gemcitabine and MK-8776 on cell cycle
perturbation of MiaPaCa-2 cells. Cells were incubated with 0 – 200 nM
gemcitabine for 6 h, then the drug was removed and cells incubated for
up to 72 h (left). One set of cells (right) were also incubated with 1 μM
MK-8776 from 18-24 h. Figure S3. Impact of gemcitabine on cell cycle
perturbation in AsPC-1 (top) and MiaPaCa-2 (bottom) tumor xenografts.
Tumors from untreated mice, or mice administered 150 mg/kg
gemcitabine were harvested at 18 h. Serial sections from the tumors
were stained for Ki67 and geminin. Representative immunohistochemistry is
shown. Quantification is presented in Figure 5.
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